Business Wire

WORKATO

5.5.2021 01:03:06 CEST | Business Wire | Press release

Share
Workato Commits Further Investment in EMEA After 289% Surge in Usage Over Last 12 Months in the Region

Workato , the leading enterprise automation platform, has today launched its first EMEA data centre in Frankfurt, Germany. The new data centre has been set up in response to exceptionally strong growth in the EMEA region, the company has seen a 289% increase in data usage on its platform from EMEA in the last 12 months. The launch of the data centre is part of the company’s strategy to boost investment twofold in the region and will provide Workato customers with a centralised location for hosting their data and provide assurance that their data residency requirements including GDPR are fully compliant and that their data is secure and protected.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210504006038/en/

The opening of the data centre in Frankfurt is testament to the strong demand Workato is seeing from European enterprises for its integration-led automation.

Workato supports customers throughout EMEA with operations currently in Spain, UK, Germany, France, Ireland, Netherlands and Italy. In January this year, the company announced Series D funding worth $110 million to be used to invest in developing its technology and expanding product innovation to help more companies around the world transform the way they work. Workato’s current customer base comprises of companies from the tech, financial services and fintech, transport and logistics, ecommerce and retail industries and include TFG Transfracht (Deutsche Bahn Group), Box, World Economic Forum (WEF), Showpad, Jumia and WorldRemit. As part of the company’s mission to improve the way enterprises work, Workato forms strategic partnerships with organisations such as Deloitte.

Markus Zirn, SVP of Strategy & Business Development at Workato commented: “The pandemic saw digital transformation catapulted to the top priority for enterprises. With increased focus on digital strategies and remote working, EMEA enterprises quickly recognised the need for automation platforms like Workato to achieve automation at scale by easily, reliably, and securely connecting applications, data, and business processes so teams can work smarter and faster.”

He added: “In response to this very strong demand for our technology across EMEA, we have invested in this new data centre, serving our European customers to ensuring their data is held in full compliance with new EU-data regulations, eliminating any risk and allowing us to help more and more businesses within the EU transform the way they work. We are delighted to be investing in this very important region for Workato and to be expanding our operations in EMEA.”

Workato customer, Agatha Sick, Head of IT at TFG Transfracht said: "Workato is enabling us to automate workflows across our enterprise.” She continued, “We are excited about the launch of the data centre in Europe as this will provide us with the option to store our data in the EU and comply with the EU data protection regulations."

Mark Watson, Chief Technology Officer at WorldRemit , another Workato customer added: “Workato’s powerful low-code/no-code integration and automation platform is enabling us to achieve automation at scale. We are excited about the launch of Workato’s Data Center in the European Union as it will enable us to keep our data close to home.”

Workato allows companies to maximise the value of their apps, data and people by making it easy to integrate disconnected data and applications, and securely automate workflows to accelerate business outcomes. Workato’s no code/low code platform combines enterprise-grade integration and automation capabilities in a single platform that is trusted by IT and easy to use for the business. With Workato, IT and business teams can more easily collaborate to rapidly integrate data, processes, applications and user experiences in almost any combination without compromising security and governance.

About Workato

Workato is the leading Enterprise Automation Platform. Recognised as a leader, Workato is the only enterprise platform that enables both business and IT to integrate their apps, automate business workflows, and drive real time outcomes from business events, without compromising security and governance. Workato is trusted by over 7,000 of the world’s top brands and fastest growing innovators.

Link:

ClickThru

Social Media:

https://www.facebook.com/workato

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye